International Journal of Entomology Research
www.entomologyjournals.com
ISSN: 2455-4758
Received: 08-11-2024, Accepted: 09-12-2024, Published: 24-12-2024
Volume 9, Issue 12, 2024, Page No. 146-152

An overview of insect derived bioactive compounds with therapeutic potential

Praveen Javali R[1], Issac V[2], Cherian[2], Abhishek Vijukumar[2], Nair Aiswarya Hemachandran[3]
[1] Department of Pharmaceutics, Sri Raghavendra College of Pharmacy, Chitradurga, Karnataka, India
[2] Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, India
[3] Department of General Medicine, Government Medical College, Miraj, Pandhrpur road, Sangli, Maharashtra, India

Abstract
Insects, among the most diverse groups of organisms, provide as a significant source of bioactive chemicals with therapeutic potential, historically utilized in medicine via honeybee products such as propolis and Apitoxin. Progress in molecular biology has unveiled their antibacterial, anti-inflammatory, anticancer, and neuroprotective properties. Antimicrobial peptides (AMPs) such as defensins and cecropins demonstrate effectiveness against drug-resistant bacteria, whereas bee venom, royal jelly, and propolis possess antioxidant and immunomodulatory characteristics. Challenges encompass sustainability, chemical variability, and scalability for pharmaceutical applications. Synthetic biology and biotechnology provide solutions; yet, ethical, regulatory, and quality concerns remain. This domain emphasizes the necessity of safeguarding insects and tackling global health issues such as antibiotic resistance and cancer, which could revolutionize pharmacological methodologies.

Keywords: Insect-derived bioactive compounds, antimicrobial peptides, bee venom, propolis, silkworm proteins, neuroprotection, therapeutic potential, synthetic biology, cancer therapy, wound healing

Introduction

Insects, some of the richest and most diverse inhabitants of our planet, are storehouses of bioactive substances which hold great promise as drugs. This group of animals has so far been described in more than a million species, and who knows how many millions more remain unrecognized there is enough evidence that clearly indicates that they are indispensable partners in the regulation of ecosystems and provide a unique resource for developing new drugs that has not been fully exploited. In ancient days, bugs have played a significant role within the different traditional healthcare practices across the global, in the provision of solutions to various diseases and conditions. Honeybee products are used in traditional medicine similarly to silkworm derivatives and various insect venoms that have been officially recognized for a long time. Nonetheless, serious scientific research into these compounds has only begun in the recent past on account of the progress made in the field of analytical chemistry, molecular biology as well as pharmacology [1]. Using sophisticated techniques in the analysis, purification, and assessment of insect derived bioactive compounds proved potential pharmaceutical benefits. The obtained compounds demonstrate effectiveness in the context of such activities as antimicrobial, anti-inflammatory, anticancer, antioxidant and neuroprotective ones. For example, antimicrobial peptides (AMPs) that are secreted by insects in the fight against drug-resistant pathogens, a rapidly emerging problem in the world's health systems. Likewise, venom peptides are under research for use in anticancer and analgesic treatment because the principle of action involving the venom always seem to have a preference for cancerous cells or the pain pathways. Bees such as honey contains bioactive ingredients such as antioxidants against honeybee propolis and immunomodulatory effects of royal jelly, silkworm proteins that possess anti-inflammatory effects that enhance wound healing, with an example being sericin. These observations only serve to illustrate the tremendous potential of insects as source of new therapeutic compounds. Nevertheless, these potentials have the following limitations in their transition from compounds derived from insects to mainstream medicine. One of the issues that arise from harvesting of these products is sustainability they are harvested. Excessive use of insects can indeed be misleading and dangerous for the balance of ecosystems and the biodensity; it is enough to mention the case with bees, because many ecological and agricultural processes depend on them. Other crucial issues that also deserve consideration concerning ethical issues are the manner in which insects are handled during the harvest. Developing sustainable farming practices and employing synthetic biology techniques to produce bioactive compounds without large-scale insect farming offer potential solutions. Insect coderivatives have inspired advancements in bioanalytical methods, such as the development of highly sensitive LC–MS/MS-ESI techniques, which facilitate precise determination of compounds like phenelzine in human plasma for pharmacokinetic studies [2, 3].

Historical context

Traditional usage of insects has a long and rich historical background where use of insects in the treatment and management of diseases has been documented. Sumerians, Egyptians, Asians, Africans, and even Native American civilizations have all recorded how they used insects for therapeutic purposes relying sometimes on folk wisdom and sometimes on actual research. The most famous example of them are honeybee products being widely used in ancient medicine. Being classified as nature's gift to mankind, honey was taken by Egyptians, Greeks and Romans for its wound healing properties and natural preserving abilities. Beeswax, a substance extracted from bees, was used as a laxative, whilst propolis which is a resin like substance collected by bees for its antimicrobial and anti-inflammatory properties. For instance, insects have had a central position in the Chinese medicine over the centuries that precede the widely recognised period [4]. Three important lepidopteran worms; Bombyx mori were used in the treatment of seizures, paralysis, and skin diseases. Sore throats and heat clearances – cicadas were dried for this purpose. Blister beetles which are prevalent in both Europe and Asia were used to synthesize cantharidin a dangerous compound used for procedures such as wart. Blister beetles found in Europe and Asia were used to derive cantharidin, a dangerous substance used in removing warts and treating other skin ailments. As for insects, people of the different aboriginal civilizations of the world have exercised insect-therapy methods. In South America, extracts from ants, wasps, and termites were used for treating bacterial and chronic infections, cuts and inflammation. Termite mounds and the termites were included in the treatment of such diseases like gastrointestinal and respiratory diseases in Africa. People of America, particularly Native American depended on the grasshoppers and crickets both for food and for their curative value. Insect-derived codrugs offer a novel dimension in cassette dosing strategies, potentially enhancing the metabolic stability and bioavailability of compounds during high-throughput pharmacokinetic screening in drug discovery [5, 6, 7].

Sources of bioactive compounds from insects

Insects form a very large group but are a largely unexplored source of bioactive compounds with great potential as therapeutic agents. This group of compounds is obtained from the venoms, secretions, exoskeletons, metabolites, and symbiotic microorganisms, and the molecules have been observed to exhibit versatile pharmacological profiles. The fact that a number of insect species has been show to possess significant levels of bioactivities only serve to support the position that insects could be a rich source of lead compounds for drug discoveries. In this article, an extensive review of insect bioactive compounds is given based on its source, chemical property and pharmacological uses. Some of the most investigated insects are honeybees (Apis mellifera) whose workers secrete numerous bioactive compounds with pharmacological uses as has been well illustrated. For instance, honey is a sophisticated biomaterial that contains sugars and enzymes, hydrogen peroxide, flavonoids, and phenolic acids. In this composition, honey is allotted antimicrobial and wound-curing properties that makes it a fundamental remedy in traditional medicine as well as modern medicine wound treatment. Further, honey has antioxidant property since it has phytochemicals which help in combating oxidative stress associated with most chronic diseases Insect coderivatives, often studied as protein-bound biomarkers or enzyme substrates, provide unique insights into drug-protein interactions, offering a novel perspective on how binding dynamics influence drug pharmacokinetics, efficacy, and safety [8]. Propolis, the second honeybee product, is a resin which honeybees harvest from the plant secretions. Globally, propolis contains flavonoids, phenolics and aromatic acids that have been scientifically proven to have anti inflammatory, antimicrobial and antioxidant properties. It has usage in curing infections; used in the management of inflammation in chronic diseases. Royal jelly which is special substance feed solely to the larvae and the queen bees consist of protein, lipids and vitamins. In this composition, royal jelly is endowed with immunomodulating, neuroprotective and anti-aging properties which make it useful for diseases arising from immuno-compromised states, neuro-degenerative illnesses and ageing. Another important source [of bioactive compounds] is silkworms (Bombyx mori) because they contain proteins and enzymes. Sericin and fibroin are potential silk proteins that endowed with antioxidant, anti-inflammatory, and wound healing potential. These proteins have been receiving much attention in dermatology and tissue engineering, due to their suitability to be used as bio degradable materials in skin repair and regeneration. In addition, the silkworms release another type of peptides known as serrapeptase, which possess inflammatory and blood clots reducing properties. Serrapeptase is used for ailments related to arthritis, atherosclerosis and chronic inflammation and hence proves the usefulness of products from silkworms. Beetles are also essential pharmacologically especially the blister beetles since they contain cantharidin. This vesicant compound is used as an anticancer and antiviral substance and as a traditional remover of warts and anti-tumor. Cantharidin today is used in various fields: reconstructive and aesthetic surgery, gynecology and oncology and is being actively developed. Butterflies and moths present other compounds with bioactivities including pigments with antioxidant and anti-inflammatory activities. It was found that some moth species excrete antimicrobial and anticancer compounds, therefore substantiating the existence of many bioactive molecules belonging to the Lepidoptera order. Ants also belong to the insects that synthesize bioactive substances with therapeutic potency. For instance, formic acid has antimicrobial potential and it is learnt, the slice has been employed traditionally for treating diseases. Analgesic and ant-inflammatory properties of venom alkaloids produced by certain species of ant are seen to open up further pharmacological uses of these small but versatile insects. Likewise, wasp venom has the following peptides: melittin and mastoparan that exhibit antimicrobial, anticancer, and anti-inflammatory properties. These peptides are however being researched as potential candidates for new pharmacological agents in diseases of infection, cancer and inflammation [9]. From the relationship with microbes, termites produce peptides for antibiotic action against drug-resistant bacteria and fungi. The relationship that termites have with their microbial partners makes this regard a goldmine of bioactive compounds that research can tap to fight the emerging challenge of antimicrobial resistance. Grasshoppers and crickets, whose products are widely used in human diets because of the nutritional value, contain other bioactive compounds like chitin and chitosan. These polysaccharides have been regarded as possessing antibacterial, antifungal, and wound healing activity and have been used extensively in biomedicine and food conservation. Some examples of these polymers are drug delivery systems, biodegradable wound dressings and antimicrobial coatings. Bioactivities of cockroaches and dragonflies are also under investigation. Various extracts derived from the cockroach, and which are traditionally utilized in Chinese medicine, are investigated as having both wound-healing and antimicrobial properties. Programmed peptides derived from dragonflies proved high efficacy towards thedrug-resistant bacterial strains, the insect having therapeutic potential for drugresistant infections. On the bioactive compounds level, insects contain microbial biota generating secondary products too as antibiotics and enzymes. these metabolites provide additional targets for drug discovery, targeting mdr pathogens for identification of new drug molecules. Such chemical heterogeneity is parallel by the spectrum of diseases the insect borne compounds are known to treat. For example, antimicrobial peptides (AMPs) derived from insects are currently considered as the possible substitute of antibiotics. These peptides acted on the microbial membrane and had a different mode of action to the regular antibiotic and, therefore, are less likely to be resisted by pathogens. In the context of pharmacy practices, the growing sophistication of digital tools, akin to the adaptability seen in insect co-derivatives, mirrors the evolution of challenges and innovations in aligning technological advancements with HIPAA's patient privacy protections [10]. Consequently, pharmacological peptides present in bee, wasp, and ant venoms are under investigation for pain relief and cancer treatment. Based on the understanding that melittin, one of the bee venom components, can selectively kill cancer cells and avoid normal cells, it has a good therapeutic effect. Insects also provide answers to the integrated and chronic inflammatory diseases. Biochemicals like serrapeptase extracted from the silkworm as well as venom alkaloids from ants and wasps have been considered to be anti-inflammation compounds, and therefore they can be used in health problems such as arthritis, asthma, as well as inflammatory bowel disease. Compounds derived from honey, propolis and silk proteins also have antioxidant effects which make them a formidable combatant of oxidative stress illnesses such as neurodegenerative diseases and cardiovascular diseases. Therefore, while there seems to be an almost limitless assortment of compounds obtainable from insects that could be applied to modern medicine, the use of such insect-derived compounds in medicine presents several problems. Each individual component of the compounds however may differ being dependent on factors such as species, diet and environment. Such considerable fluctuations complicate the task of achieving stability in the quality and effectiveness of these compounds for therapeutic applications [11].

Therapeutic Potential of Insect-Derived Compounds

1. Antimicrobial activity

Insects are well-known sources of antimicrobial peptides (AMPs) which are the parts of innate immune system for insects, their pathogens being bacteria, fungi and viruses. These peptides include defensins, cecropins and attacins that target both Gram positive and Gram-negative bacteria and other microorganisms through cell membrane damage causing cell death. This mechanism is especially efficacious against drug-resistant pathogens which is a plus given that the world is facing an antibiotic resistant challenge. Compositions of cecropins from silkworms and defensins from honeybee have been proven to work on the multidrug-resistant bacteria to embark the importance of therapeutic points. However, honeybees are not limited to, producing AMPs, and they have other antimicrobial compounds as well. Because honey has low pH and high osmolarity and hydrogen peroxide, antibacterial activity is exhibited while wound healing is enhanced. Propolis refers to resins collected, stored, and used by bees, this product contains flavonoids and phenolic acids especially used for their antimicrobial and anti-inflammatory effects. These natural products can also eliminate pathogen and at the same time, they also help in the regulation of the immune system against infections. The development of new antimicrobials from insect sources is a huge untapped resource in the modern world. Therefore, by using the distinctive features of AMPs and other bioactive compounds, researchers endeavor to develop perspective substitution for traditional antibiotics for one of the most critical problems of the modern healthcare system [12, 13].

2. Anticancer properties

Bioactive compounds from insects are becoming the focus of interest due to their antineoplastic properties. Melittin, the peptide present in bee venom, triggers the apoptotic process of dying in cancer cells: it destabilises membranes of cancer cells and stimulates apopto- sis-mediated and caspase-dependent pathways. Naturally occurring flavonoids chrysin and CAPE from propolis derived from bee proved to possess the ability to arrest tumor growth and angiogenesis. Cantharidin is isolated from blister beetles and is highly selective for cancer cells acting through interference with phosphatase 2A (PP2A) and apoptosis. Also wasp venom has mastoparan, the peptide which affects the mitochondrial membranes in the cancer cells thus leading to cell death. These compounds derived from insects are quite selective in their cytotoxicity, the ability of cancer cells to be killed specifically without affecting the normal surrounding cells more than conventional chemotherapy eliminates the unwanted side effects. The targeted and novel modes of action of these compounds suggest that these molecules might be suitable for use as complementary or additional therapies in cancer treatment, perhaps providing milder means of cancer treatment than conventional ones [14].

3. Antioxidant activity

Oxidative stress is related to many chronic ailments, making insect sourced conjugates a useful source of antioxidants. On comparing the peptide and fatty acid content of royal jelly with that of other proteins and lipids, royal jelly exhibit higher free radical scavenging activity. These antioxidants keep cells from oxidative damage which is very useful in lowering of the risk in cardiovascular diseases and neurodegenerative diseases. Sericin and fibroin proteins that are constituent of the silkworm also show remarkable antioxidant activity. They scavenge radicals that form reactive oxygen species (ROS) and boosts the body anioxidant capacity. Propolis, which is a bee collected substance that resembles resin, is abundant in phenolic compounds and adds to the role of defending the cells under oxidative stress. These antioxidant containing compounds obtained from insects are thought to have potential therapeutic applicability in preventing and curing diseases, which are defined by oxidative stress. If aimed at oxidative stress, they might decrease the incidence of heart disease, Alzheimer’s, and various other age-related diseases. As these gentles demonstrated the antioxidant activities these natural compounds play a significant role in maintaining human health and arresting the advancement of diseases associated with oxidative stress [15].

4. Wound healing

Insect derived products for wound healing purposes are slowly receiving the recognition they deserve. Honey, used as an effective antimization remedy, which has antibacterial, antiviral and tissue healing properties. It speeds up the rate of ulceration mainly by providing a moist environment hence promoting formation of new blood vessels and collagen fiber proliferation which are critical for tissue regeneration. Wound healing is promoted through the formation of protective coatings and support for cells regeneration using chitosan derived from grasshopper and cricket exoskeletons. This rectification makes it an essential additive in wound management since it enhances the specific essential wound closing and reduces chances of getting an infection. Another insect product is propolis that is known to possess antibacterial and anti-inflammatory effects, needed when there are incidences of infections and tissue repair involved in case of injury. Such insect derived compounds are relatively cheaper and more effective compared to other options where advancement in wound care treatments is limited. Due to their naturality, when used as developed here, and their efficacy in managing wound infections and healing, they qualify to be embraced as effective icons in wound care provision in clinical and low-resource settings. Consumption of such products is beneficial in this regard not only because it provides the given solution, but because it shows the possibility of traditional solutions based on the nature's gifts in the context of contemporary medicine [16].

5. Neurological disorders

There is growing evidence that bioactive compounds from insects have the potential to be acting as treatment agents of neurological disorders. For example, royal jelly is reported to obtain the neuroprotective function mainly from 10-hydroxy-2-decenoic acid (10-HDA). This compound stimulates the formation of neurons in the brain and protects cells from oxidation, and so royal jelly has the potential for use in senile dementia, Alzheimer's, and Parkinson's diseases. Silk proteins derived from silkworms may well have anti-neurodegenerative properties by decreasing oxidative stress and promoting nerve repair, which could prove valuable in managing a range of neurologic diseases. Moreover, bee venom peptides have a neurological property that make them useful in cases of multiple sclerosis management. These compounds derived from insects not only have the natural neuroprotection activity but also suggest a new prospective towards the treatment of associated diseases including neuronal damage and dysfunction. These compounds extended potential of new neurotherapeutic strategies because they foster neurogenesis, protect against oxidative stress, and facilitate nerve regeneration. Given this avenue of study, these compounds might have a significant utility in the development of novel treatment techniques for Neurological disorders [17].

Mechanisms of action

Bioactive chemicals derived from flora and fauna, including insects, present therapeutic potential by processes such as membrane disruption, signaling pathway modulation, and antioxidant action. Peptides produced from insects, such as cecropins and melittin, demonstrate antibacterial and anticancer effects by targeting cell membranes and selectively eliminating infections or tumor cells [18, 19]. Melittin diminishes inflammation by inhibiting NF-κB, rendering it useful against inflammatory conditions such as rheumatoid arthritis and cancer. Royal jelly peptides modulate insulin signaling, presenting opportunities for the management of diabetes and metabolic diseases [20]. Enzymes such as serrapeptase derived from silkworms mitigate inflammation and facilitate tissue healing, whilst enzymes in termite saliva enhance digestion and metabolism. Antioxidants in royal jelly and sericin from silk demonstrate potential in mitigating oxidative stress associated with aging, neurological disorders, and cardiovascular diseases. These molecules offer a wide range of therapeutic uses, targeting infections, cancer, inflammation, and chronic illnesses [21]. Bioactives derived from insects offer environmentally sustainable and novel solutions for rising global health issues [22].

Challenges in utilization

Antibiotic-free insect bioactive compounds have become widely used in therapeutic contexts as mentioned in Table 1; however, their potential large-scale utilization raises numerous issues concerning sustainability and ethicality, highly productive insect biomaterial obtaining, safety, and essential permits. That is why research in these areas particularly targeting broad spectrum of diseases is so important for the further utilization of insect-derived compounds in therapeutic practice. This brief review shows that the overexploitation of insects is one of the major drawbacks associated with the use of insect-derived bioactive compounds. For instance, honey bees, which are getting used for bee sting and venom, honey as well as others are under increased threat from loss of their habitat, pesticides and climate change. The increasing pressure for insect products translate to negative impacts as their population reduces thereby affecting ecosystems and biodiversity [23]. This raise concerns scientifically given the importance of insect and more so pollinators such as bees to plant species and ecosystem services. Excessive collection of these insects might interfere with these useful capabilities; it become an obvious ecological and ethical question. But, in order to reduce the effects of over exploitation sustainable farming methods must be practiced. A related possibility includes the use of semi-natural and enclosed settings to rear insects for the desired compounds, and the biological control would absolutely not depend on wild insects here. However, such methods have to be set with well being of the insects into consideration so that they do not upset the ecological balance. Besides, synthetic biology has been developed to be a strong approach to such challenges of sustainability. Since ergothioneine production using microbial or cell culture systems is feasible, the three-step process eliminates the need for intensive insect farming. Melittin and sericin are examples of insect-produced compounds which could be produced through genetic engineering of bacteria or yeast in a sustainable, reproducible manner. In terms of ecological vulnerability this biotechnological approach could considerably decrease dependence on insect populations and stabilise the production process. However, this type of compounds has not been fully developed from insects due to a variety of factors, including variability of chemical content of samples. These compounds' composition depends on many factors, such as an insect species, its diet, the surrounding environment, and even the time of the year when the compounds are collected. This variability makes it difficult for be developed of bioactive compounds in medical treatment because of variation in potency and purity. For instance, the honeybee venom obtained from various hives or at different period may contain different weight of peptide including melittin that can determine the effectiveness of the medication [24]. This problem can only be solved through the development of strict guidelines for the isolation, purification and identification of insect-derived bioactive substances. These protocols should consider the many factors that determine the nature of a compound, that each batch produced by the end should have similar quality and strength. Standardization procedures drawn out should contain tests for purity, concentration and biological activities of the compounds and an excellent record on the environment under which the compounds were synthesized. These steps are crucial in order to ensure that products derived from insects fulfil the medical standard and quality that make them safe for human consumptions [25].

Other problems, such as sustainability, standardization, and the ability to manufacture at a larger scale, are also major issues considering the extensive utilization of insect-derived bioactive compounds. Many widely-executed practices like venturing for bee venom or banishing honey are time-consuming, inefficient ways of getting the product done for mass production. These insect-derived compounds have not been fully commercialized, and the needed large-scale production of such solutions has not been feasible due to technological restrictions. In order to address this issue, there is need to explore further in the realization of biotechnology and genetic engineering. Such compounds may be produced in large scales using microorganisms or cultured cells as an alternative to current insect collection methods. The down-stream processing and labor-cost attachment in the generation of insect derived compounds have been a hindrance in large scale usage in healthcare industries which could be solved by biotechnology improvements. One of the most important factors to check when using insect derived bioactive compounds in treatment, is safety. Certain of those compounds like melittin in bee venom could provoke an allergy, especially in people with certain level of sensitivity. These reactions can be as mild as skin rashes, and as severe as anaphylactic reactions, which are life threatening to the patient. Moreover, majority of the compounds retrieved from insects are known to possess toxicological effects at their optimal concentrations and thus their efficacy may be restricted. As a result, proper preclinical and clinical trials are the key to the security of these compounds [26]. Such research must determine the safety of insect-based compounds and their sensitizing capacity, and side effects that include any endeling effects or drug-interaction effects. Many safety issues can arise due to the usage of these compounds that is why, to manage the potential side effects and to achieve better therapeutic outcomes the dosage must be properly controlled. Last but not the least; due to stringent regulatory requirements for approvals which contributes to the increasingly bund of approvals of products that contains insect derived bioactive compounds in medicine. Before any new therapeutic can get to the market, regulatory bodies like FDA in the United States, or EMA in Europe expects sufficient proofs of the safety, efficiency as well as quality of the new therapeutic products. This process may take a long period of time, expensive and consumes many resources thus becoming a challenge to the early development and marketing of insect derived therapeutics. In addition, there is no clear set of standards to regulate the products of insect bioactive compounds due to the Insect-derived compound is often not easily classified under pharmaceuticals or biologics. More efforts need to be made by the researchers and industrial players in collaboration with the respective regulatory bodies to set right guidelines and redouble efforts to fast-track these promising treatments [27].

Table 1: Proposed methods, strategies, or technologies to address the identified issues and ensure sustainable and ethical utilization of insect-derived compounds

Aspect	Key Issues	Potential Solutions/Recommendations
Sustainability	Overexploitation of insects (e.g., honeybees) threatens ecosystems and biodiversity.	- Sustainable farming practices. - Use of semi-natural/enclosed settings to rear insects. - Leverage synthetic biology for alternative production methods.
Standardization	Variability in chemical content due to factors like species, diet, environment, and collection timing affects potency and purity.	- Develop strict guidelines for isolation, purification, and identification. - Standardize protocols for purity, concentration, and biological activities.
Scalability	Time-consuming and inefficient practices for obtaining compounds (e.g., bee venom extraction) hinder large-scale production.	- Use biotechnology and genetic engineering to produce compounds via microorganisms or cell culture. - Improve downstream processing to reduce costs.
Safety	Compounds like melittin may provoke allergies or have toxicological effects at optimal concentrations.	- Conduct thorough preclinical and clinical trials. - Determine sensitizing capacity, side effects, and proper dosage for therapeutic use.
Regulatory Challenges	- Regulatory approvals are time-consuming and expensive. - Lack of clear classification standards for insect-derived compounds (pharmaceuticals or biologics).	- Collaborate with regulatory bodies to establish clear guidelines. - Fast-track regulatory processes for promising treatments.
Technological Limitations	Limited feasibility for mass production of insect-derived bioactive compounds.	- Invest in biotechnological advancements and genetic engineering. - Explore microbial or cell culture systems for sustainable production.
Ethical and Ecological Concerns	Excessive collection disrupts insect roles (e.g., pollination) and ecological balance.	- Prioritize insect welfare in farming methods. - Reduce dependence on wild insect populations through biotechnological solutions.

Opportunities and future directions

Molecular biotechnology and synthetic biology have helped rationally and efficiently regulate termite bioactive chemicals to replace insectary rearing. These have substantially improved the generation of insect sources of bioactive chemicals like antimicrobial peptides (AMPs), venom peptides, and hundreds of other compounds utilizing Escherichia coli or yeasts. They are more efficient than farm-raised insects and can be genetically manipulated to synthesize bioactive compounds from insect sources. Synthetic biology improves chemical control in the production process. Researchers can improve the efficacy, stability, potency, and selectivity of bioactive chemicals by modifying their genes [28]. This fine tuning is essential to determining the safety and efficacy of bioactive substances in treating cancer and infections [29, 30, 31, 32].

Conclusion

Insect-derived bioactive compounds are a new area of drug development and applied treatments. These chemicals offer radical solutions to many global health concerns due to their unique chemical properties and innovative interactions with biological targets and systems. However, achieving them entails overcoming sustainability and scalability obstacles, legal limits, and ethical concerns. The first concern is insect-collected compound sustainability. Destructive bee-taking practices harm ecosystem plants and species. Bees pollinate; therefore, their extinction could hurt agriculture worldwide. Gentle farming and habitat conservation reduce these affects. Synthetic biology allows bioactive chemicals to be synthesized utilizing microbial or cell culture systems, solving the constraints of insect-derived bioactive substances. This ensures a consistent source and addresses environmental and animal rights concerns. Bioactive compound yield variability is another major issue that affects quality and efficacy. Inconsistencies are caused by bug species, diet, or environment. Cordial extraction and purification procedures and genetic engineering advancements can help ensure these substances' dependability. Proper quality management is essential to turning natural goods into effective therapeutics. Scalability and high production costs are another difficulty with insect-derived bioactive chemicals. Traditional harvesting methods are too slow for large-scale farming. Recombinant DNA and fermentation principles enable cost-effective manufacturing scalability. These methods can enhance yield without increasing environmental impact or expenses, which could help commercialize insect-derived therapies. Synthesis of these chemicals must also overcome safety hazards due to their design. Although many insect-derived chemicals have excellent pharmacological characteristics, some, like venom peptides, can cause allergy and toxicity at high quantities. Preliminary and comprehensive investigation needed to build safety profiles and dose limits for compound selection. When assessing patient safety, long-term side and dose-interaction profiles must be carefully considered. The last barrier to insect-derived compound adoption is regulatory restrictions that make it hard to incorporate them into systemic wellness systems. Some present frameworks don't address these products properly, resulting in protracted approval cycles. Researchers, industry, and government organizations should standardize these practices. This is done by regulating the process of turning molecules into licensed treatments and encouraging interdisciplinary cooperation.

References

1. L. Cornara, M. Biagi, J. Xiao, and B. Burlando, “Therapeutic properties of bioactive compounds from different honeybee products,” *Front. Pharmacol.*, vol. 8, p. 412, 2017.
2. J. R. RR Kallem, B Jillela, AR Ravula, R Samala, A Andy, M Ramesh, “Highly sensitive LC–MS/MS-ESI method for determination of phenelzine in human plasma and its application to a human pharmacokinetic study,” *J. Chromatogr. B*, vol. 1022, no. 8, pp. 126–132, 2016.
3. R. M. Faust and J. L. Vaughn, “Use of tissue culture and genetic engineering technology for development of microbial insects control agents,” in *Proceedings of the 36th Southern Pasture and forage Crop Improvement Conference*, 1979, pp. 8–20.
4. E. M. Costa-Neto and F. V Dunkel, “Insects as food: history, culture, and modern use around the world,” in *Insects as sustainable food ingredients*, Elsevier, 2016, pp. 29–60.
5. A Andy, “Cassette Dosing in Drug Discovery: Advantages, Limitations, and Its Role in High-Throughput Pharmacokinetic Screening,” *Int. J. Innov. Res. Eng. Multidiscip. Phys. Sci.*, 2019.
6. S. K. Srivastava, N. Babu, and H. Pandey, “Traditional insect bioprospecting–As human food and medicine,” 2009.
7. P. W. C. Green, “Insect-derived compounds affect the behaviour of Liposcelis bostrychophila: effects of combination and structure,” *J. Stored Prod. Res.*, vol. 47, no. 3, pp. 262–266, 2011.
8. A Andy, “The Role of Protein Binding in Drug Pharmacokinetics Implications for Drug Efficacy and Safety,” *Int. J. Innov. Res. Eng. Multidiscip. Phys. Sci.*, 2019.
9. P. Dutta, R. K. Sahu, T. Dey, M. D. Lahkar, P. Manna, and J. Kalita, “Beneficial role of insect-derived bioactive components against inflammation and its associated complications (colitis and arthritis) and cancer,” *Chem. Biol. Interact.*, vol. 313, p. 108824, 2019.
10. A Andy, “The Role of HIPAA in Protecting Patient Privacy in Pharmacy Practices: Challenges and Innovations in the Digital Age,” *Int. J. Multidiscip. Res.*, vol. 2, no. 10, pp. 1–9, 2020.
11. O. Schlüter *et al.*, “Safety aspects of the production of foods and food ingredients from insects,” *Mol. Nutr. Food Res.*, vol. 61, no. 6, p. 1600520, 2017.
12. P. Bulet, C. Hetru, J.-L. Dimarcq, and D. Hoffmann, “Antimicrobial peptides in insects; structure and function,” *Dev. Comp. Immunol.*, vol. 23, no. 4–5, pp. 329–344, 1999.
13. L. Seabrooks and L. Hu, “Insects: an underrepresented resource for the discovery of biologically active natural products,” *Acta Pharm. Sin. B*, vol. 7, no. 4, pp. 409–426, 2017.
14. B. Sinha and Y. Choudhury, “Revisiting edible insects as sources of therapeutics and drug delivery systems for cancer therapy,” *Front. Pharmacol.*, vol. 15, p. 1345281, 2024.
15. M. C. Nino, L. Reddivari, C. Osorio, I. Kaplan, and A. M. Liceaga, “Insects as a source of phenolic compounds and potential health benefits,” *J. Insects as Food Feed*, vol. 7, no. 7, pp. 1077–1087, 2021.
16. S. Roy, S. Saha, and P. Pal, “Insect natural products as potential source for alternative medicines-a review,” *World Sci. News*, vol. 19, pp. 69–83, 2015.

17. S. Bhola, E.-J. Park, and H.-J. Lee, "Insect-derived extracts and peptides in neuroprotection," *Nutr. Neurosci.*, pp. 1–9, 2024.
18. E. E. Oghenesuvwe and C. Paul, "Edible insects bio-actives as anti-oxidants: current status and perspectives," *J. Complement. Med. Res.*, vol. 10, no. 2, pp. 89–102, 2019.
19. G. Lee and H. Bae, "Anti-inflammatory applications of melittin, a major component of bee venom: detailed mechanism of action and adverse effects," *Molecules*, vol. 21, no. 5, p. 616, 2016.
20. N. A. Ratcliffe, C. B. Mello, E. S. Garcia, T. M. Butt, and P. Azambuja, "Insect natural products and processes: new treatments for human disease," *Insect Biochem. Mol. Biol.*, vol. 41, no. 10, pp. 747–769, 2011.
21. L. Flohé, S. Toppo, and L. Orian, "The glutathione peroxidase family: Discoveries and mechanism," *Free Radic. Biol. Med.*, vol. 187, pp. 113–122, 2022.
22. M. H. Baig *et al.*, "Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases," *Biomed. Pharmacother.*, vol. 103, pp. 574–581, 2018.
23. D. Rajkhowa and M. K. Deka, "Insect-based medicines: a review of present status and prospects of entomo-therapeutic resources for human ailment," *Int. J. Agric. Environ. Biotechnol.*, vol. 9, no. 6, pp. 1069–1079, 2016.
24. S. A. Siddiqui *et al.*, "Unravelling the potential of insects for medicinal purposes–a comprehensive review," *Heliyon*, vol. 9, no. 5, 2023.
25. N. Ratcliffe, P. Azambuja, and C. B. Mello, "Recent advances in developing insect natural products as potential modern day medicines," *Evidence-Based Complement. Altern. Med.*, vol. 2014, no. 1, p. 904958, 2014.
26. M. R. Mishra and M. Puzari, "The practice of entomotherapy with a focus on North-East India," *Orient. Insects*, pp. 1–18, 2024.
27. G. F. Ferrazzano, F. D'Ambrosio, S. Caruso, R. Gatto, and S. Caruso, "Bioactive peptides derived from edible insects: effects on human health and possible applications in dentistry," *Nutrients*, vol. 15, no. 21, p. 4611, 2023.
28. M. Tonk and A. Vilcinskas, "The medical potential of antimicrobial peptides from insects," *Curr. Top. Med. Chem.*, vol. 17, no. 5, pp. 554–575, 2017.
29. G. Kaur, P. S. Sarao, and N. Chhabra, "Therapeutic use of insects and insect products," *Indian J. Entomol.*, pp. 798–807, 2023.
30. J. Xia, C. Ge, and H. Yao, "Antimicrobial peptides from black soldier fly (Hermetia illucens) as potential antimicrobial factors representing an alternative to antibiotics in livestock farming," *Animals*, vol. 11, no. 7, p. 1937, 2021.
31. E. Mylonakis, L. Podsiadlowski, M. Muhammed, and A. Vilcinskas, "Diversity, evolution and medical applications of insect antimicrobial peptides," *Philos. Trans. R. Soc. B Biol. Sci.*, vol. 371, no. 1695, p. 20150290, 2016.
32. D. Brady, A. Grapputo, O. Romoli, and F. Sandrelli, "Insect cecropins, antimicrobial peptides with potential therapeutic applications," *Int. J. Mol. Sci.*, vol. 20, no. 23, p. 5862, 2019.